Stanislas POL

Prof. Stanislas POL

Université de Paris; Inserm U-1223 et Immunité des cellules dendritiques, Institut Pasteur; Département d’Hépatologie, APHP, Hôpital Cochin; Paris, France
+1

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2023 in JHEP Reports
Verified
Journal Article
Open access
SPStanislas POL
Stanislas POL
MSMehdi Sakka
Mehdi Sakka
ARAurelia Retbi
Aurelia Retbi
SBSamir Bouam
Samir Bouam
LHLamia Hassani
Lamia Hassani
PTPatrick Tilleul
Patrick Tilleul
There is concern about the burden of liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). In a retrospective cohort study, we evaluated the likelihood of grade 3/4 liver injury, of grade 3/4 cholestatic liver injury, and of liver failure, as per the Common Terminology Criteria for Adverse Events (CTCAE) version 5, following treatment with ICIs. We compared these occurrences with a group of cancer patients who were propensity-matched and treated with conventional chemotherapy. For all ICI patients experiencing grade 3/4 liver injury, we conducted a causality assessment using the RUCAM method and examined patient outcomes. Among 952 patients (median [IQR] age 66 [57–73] years, 64% males) who were treated with ICI between January 1, 2015, and December 31, 2019, a total of 86 (9%) progressed to grade 3/4 liver injury, and liver failure was not observed. Anti-PD-(L)1/anti-CTLA-4 antibodies combinations (adjusted hazard ratio 3.36 [95% CI: 1.67–6.79]; p <0.001), and chronic hepatitis B (adjusted hazard ratio 5.48 [95% CI: 1.62–18.5]; p = 0.006], were independent risk factors. Liver injury was attributed to ICI treatment in 19 (2.0%) patients. Patients with ICI toxicity typically presented with granulomatous hepatitis or cholangiocyte inflammation. ICI withdrawal was associated with cancer progression and mortality. Re-introduction of ICI was not associated with recurrent grade 3/4 liver injury. Compared with matched patients treated with conventional, non-ICI-based chemotherapy, anti-PD-(L)1/anti-CTLA-4 combinations (p <0.001) and anti-PD-(L)1 monotherapies (p = 0.053) increased the risk of grade 3/4 liver injury and of grade 3/4 cholestatic liver injury, respectively. An increased risk of grade 3/4 liver injury under anti-PD-(L)1/anti-CTLA-4 antibodies was observed, whereas no substantial increase in the likelihood of liver failure occurred even after treatment reintroduction. There is concern about liver injury in patients with cancer exposed to immune checkpoints inhibitors (ICIs). We investigated the burden of grade 3/4 liver injury after treatment with ICIs in a multicentric cohort of patients with cancer. Overall, a 9% incidence of grade 3/4 liver injury was detected after ICIs, and direct ICI hepatotoxicity was demonstrated in 2% of patients. Anti-PD-(L)1/Anti-CTLA-4 antibody combinations, and chronic HBV infection were independent risk factors. ICI withdrawal for grade 3/4 liver injury was associated with cancer progression. Re-introduction of ICI treatment was not associated with recurrent grade 3/4 liver injury.

Verified
Journal Article
Open access
PDF file
SPStanislas POL
Stanislas POL
KMKennie Marcin
Kennie Marcin
BTBenoit Terris
Benoit Terris
AVAnaïs Vallet-Pichard
Anaïs Vallet-Pichard
MCMarion Corouge
Marion Corouge
SPStanislas POL
Stanislas POL
Background and aims: the side effects of immune checkpoint inhibitors (ICI) pose a problem for the clinical management of cancer patients. There is a lack of knowledge of the value of liver biopsy in patients with ICI-related drug-induced liver injury (ICI-DILI). The aim of this study was to explore the impact of liver biopsy on clinical management and response to corticosteroids, according to histological findings. Methods: We conducted a retrospective, single-center study to evaluate the biochemical, histological and clinical data of 35 patients with ICI-DILI between 2015 and 2021 in a university hospital in France. Results: Of the 35 patients with ICI-DILI (median [interquartile range] age 62 [48–73] years, 40% males) studied, 20 underwent a liver biopsy. There was no difference in the management of ICI-DILI according to liver biopsy in terms of ICI withdrawal, reduction or rechallenge. According to the histological profile, patients with toxic and granulomatous profiles had a better response to corticosteroids, while patients with cholangitic lesions had the worst response. Conclusion: In ICI-DILI, liver biopsy must not delay patient care but may be useful in identifying patients with a cholangitic profile who have a poorer response to corticosteroids.

12 August 2023 in JHEP Reports
Verified
Journal Article
Open access
POPaula Ortega-Prieto
Paula Ortega-Prieto
SPStanislas POL
Stanislas POL
FBFadila Benhamed
Fadila Benhamed
MRMarion Regnier
Marion Regnier
ICIsadora Cavalcante
Isadora Cavalcante
CPCatherine Postic
Catherine Postic
O-GlcNAcylation is a reversible post-translational modification controlled by the activity of two enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). In the liver, O-GlcNAcylation has emerged as an important regulatory mechanism underlying normal liver physiology and metabolic disease. To address whether OGT acts as a critical hepatic nutritional node, mice with a constitutive hepatocyte-specific deletion of OGT (OGTLKO) were generated and challenged with different carbohydrate- and lipid-containing diets. Analyses of 4-week-old OGTLKO mice revealed significant oxidative and endoplasmic reticulum stress, and DNA damage, together with inflammation and fibrosis, in the liver. Susceptibility to oxidative and endoplasmic reticulum stress-induced apoptosis was also elevated in OGTLKO hepatocytes. Although OGT expression was partially recovered in the liver of 8-week-old OGTLKO mice, hepatic injury and fibrosis were not rescued but rather worsened with time. Interestingly, weaning of OGTLKO mice on a ketogenic diet (low carbohydrate, high fat) fully prevented the hepatic alterations induced by OGT deletion, indicating that reduced carbohydrate intake protects an OGT-deficient liver. These findings pinpoint OGT as a key mediator of hepatocyte homeostasis and survival upon carbohydrate intake and validate OGTLKO mice as a valuable model for assessing therapeutical approaches of advanced liver fibrosis. Our study shows that hepatocyte-specific deletion of O-GlcNAc transferase (OGT) leads to severe liver injury, reinforcing the importance of O-GlcNAcylation and OGT for hepatocyte homeostasis and survival. Our study also validates the Ogt liver-deficient mouse as a valuable model for the study of advanced liver fibrosis. Importantly, as the severe hepatic fibrosis of Ogt liver-deficient mice could be fully prevented upon feeding on a ketogenic diet (i.e. very-low-carbohydrate, high-fat diet) this work underlines the potential interest of nutritional intervention as antifibrogenic strategies.

1 April 2019 in Clinics and Research in Hepatology and Gastroenterology
Verified
Journal Article
Closed access
SPStanislas POL
Stanislas POL
LSLaura Sirmai
Laura Sirmai
CDClaire-Antoinette Dupuy
Claire-Antoinette Dupuy
DGDenis Glotz
Denis Glotz
SPStanislas POL
Stanislas POL

10 January 2025 in Liver International
Verified
Journal Article
Closed access
MDMarion Delplanque
Marion Delplanque
XAXavier Amiot
Xavier Amiot
DWDominique Wendum
Dominique Wendum
FRFrançois Rodrigues
François Rodrigues
ZAZohra Aknouche
Zohra Aknouche
SGSophie Anne Georgin-Lavialle
Sophie Anne Georgin-Lavialle

5 July 2025 in JHEP Reports
Verified
Journal Article
Open access
CMCharlotte Mouliade
Charlotte Mouliade
SPStanislas POL
Stanislas POL
STStylianos Tzedakis
Stylianos Tzedakis
MCMathis Collier
Mathis Collier
SBSamir Bouam
Samir Bouam
VMVincent Mallet
Vincent Mallet
The effect of elexacaftor–tezacaftor–ivacaftor (ETI) on cystic fibrosis liver disease (CFLD) outcomes remains unknown. Thus, we investigated the association between the ETI rollout and trends in CFLD progression in a nationwide cohort. Using the French National Hospital Discharge Database (2014–2023), we measured the incidence of CFLD progression (decompensated cirrhosis, gastroesophageal variceal bleeding, primary liver cancer, or liver transplantation) before and after ETI became available (December 2019) in patients with cystic fibrosis (pwCF) aged ≥12 years. Death without CFLD progression and lung transplantation were treated as competing events. Incidence rates were compared across ETI calendar eras in both the full cohort and a 1:1 propensity score-matched sample. Analyses used Kaplan–Meier curves, Fine–Gray competing risk models, and adjusted incidence rate ratios (aIRRs). The cohort included 10,083 pwCF (median age: 19 years [IQR 14–29]; 52.6% male), with 24.6% censored pre-ETI and 75.4% post-ETI. The overall incidence of CFLD progression was 3.7 per 1,000 person-years: 25.4 pre-ETI versus 1.2 post-ETI (p <0.001). The incidence of all CFLD outcomes, including non-bleeding varices, declined post-ETI (p <0.001). In matched analyses, pwCF censored during the ETI era had a lower incidence of CFLD progression (aIRR 0.28, 95% CI: 0.18–0.43; p <0.001). In addition, deaths in pwCF occurred at an older age during the ETI era. The incidence of CFLD progression declined during the ETI rollout. While these findings suggest an association between ETI availability and improved liver outcomes, unmeasured confounders and concurrent changes in management might have also contributed. Thus, further studies are needed to confirm causality and understand underlying mechanisms. In this nationwide French cohort study of over 10,000 people with cystic fibrosis, we observed a significant decline in the incidence of cystic fibrosis liver disease outcomes following the rollout of elexacaftor–tezacaftor–ivacaftor (ETI) in December 2019. The rate dropped from 25.4 to 1.2 per 1,000 person-years post-ETI. Matched analyses confirmed a reduced risk of liver disease progression, with an adjusted incidence rate ratio of 0.28. Although the findings suggest ETI may improve liver outcomes in people with cystic fibrosis, potential confounding factors necessitate further research to establish causality and understand the underlying biological mechanisms.